Search
Xilio Therapeutics Inc
XLOAdd to Watchlist
9.220USD
-0.360-3.76%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
55.16MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.76%
5 Days
+2.33%
1 Month
+11.76%
6 Months
+2.87%
Year to Date
+2.87%
1 Year
-4.97%
Key Figures
9.570Open
9.600High
22.49KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.39%Turnover Ratio
9.580Prev. Close
9.050Low
172.99KTurnover
LossP/E Static
0.73P/B
0.00%Div Yield TTM
-23.43%ROA
16.10052wk High
0.44Volume Ratio
-58.24MNet Profit
5.78MShares
-56.7568EPS TTM
-0.10Beta
-75.20%ROE
6.46552wk Low
5.74%Amplitude
100.00%Gross Margin
55.16MMarket Cap
5.30Reward/Risk
3.17%Risk Rate
TradingKey Stock Score of Xilio Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Xilio Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xilio Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Xilio Therapeutics Inc Highlights
StrengthsRisks
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.77M.
Overvalued
The company’s latest PE is -0.16, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
20.000
Target Price
+108.77%
Upside Space
Xilio Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xilio Therapeutics Inc Info
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Ticker SymbolXLO
CompanyXilio Therapeutics Inc
CEORusso (Rene)
Websitehttps://xiliotx.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52343.700
+89.400 (+0.17%)
29687.600
-111.700 (-0.38%)
7478.100
+2.600 (+0.04%)
14749.000
-606.000 (-3.95%)
68709.000
-776.000 (-1.12%)
6304.300
+28.900 (+0.46%)
67.404
-0.564 (-0.83%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4063.590
+32.820 (+0.81%)
FAQs
What is the current price of Xilio Therapeutics Inc (XLO)?
The current price of Xilio Therapeutics Inc (XLO) is 9.22.
What is the symbol of Xilio Therapeutics Inc?
The ticker symbol of Xilio Therapeutics Inc is XLO.
What is the 52-week high of Xilio Therapeutics Inc?
The 52-week high of Xilio Therapeutics Inc is 16.10.
What is the 52-week low of Xilio Therapeutics Inc?
The 52-week low of Xilio Therapeutics Inc is 6.47.
What is the market capitalization of Xilio Therapeutics Inc?
The market capitalization of Xilio Therapeutics Inc is 53.31M.
Is Xilio Therapeutics Inc (XLO) currently rated as Buy, Hold, or Sell?
According to analysts, Xilio Therapeutics Inc (XLO) has an overall rating of STRONG BUY, with a price target of 20.00.
What is the Earnings Per Share (EPS TTM) of Xilio Therapeutics Inc (XLO)?
The Earnings Per Share (EPS TTM) of Xilio Therapeutics Inc (XLO) is -58.66.